



IPO DETAILS



Issue Opens

1st Sep 21, Wed

Issue Closes

3rd Sep 21, Fri

Min. Lot Size

24 Shares

Issue Price Band

₹603 - ₹610

Issue size

Fresh Issue: 3.28 Mn Equity Shares (₹2,000 Mn)

OFS:

6.06 Mn Equity Shares (₹3,696.36 Mn)

Face Value

₹10

Listing at NSE, BSE

Objectives of the Issue

Repayment/prepayment of certain financial facilities availed by the company.

Funding working capital requirements of the company.

General corporate purposes.

Rating

SUBSCRIBE

APPLY NOW





Company Overview

Ami Organics Ltd. is a research and development driven manufacturer of specialty chemicals with varied end usage, focussed towards the development and manufacturing of pharma intermediates for regulated and generic active pharmaceutical ingredients ("APIs") & New Chemical Entities ("NCE") and key starting material for agrochemical and fine chemicals.

Cadila Healthcare Ltd. Medichem S.A. Cadila Fabbrica Italiana Sintetici S.P.A Customers Midas Pharma GmbH Fermion OY Chori Co. Ltd.

Key Therapeutic Areas





Major Manufacturers

The company is the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.



Manufacturing Facilities


The company has three manufacturing facilities in Gujarat situated at Sachin, Ankleshwar & Jhagadia, with an aggregate installed capacity of 6,060 MTPA.






Issue Details

Issue Break-Up



Shareholding Pattern



Capital Structure (in ₹)








Valuations and Peer Comparison


Market Cap ₹22,227 Mn



Financial Snapshot (in Mn ₹)

Revenue









Business Insights



Competitive Strengths

- Strong and diversified product portfolio ably supported by strong R&D and process chemistry skills.
- Extensive geographical presence and diversified customer base with long standing relationships.
- High entry barriers in the chemicals manufacturing industry in which the Company operates.
- Strong sales and marketing capabilities.
- Experienced and dedicated management team
- Consistent financial performance.



Business Strategy

- Diversification of product portfolio by strengthening R&D capabilities.
- Augmenting scale through organic and inorganic routes in the current geographic markets and expanding into new geographic markets.
- Continue to focus on cost efficiency and improving productivity while employing environmentally friendly processes.
- Diversification of business by focussing on organic and inorganic growth opportunities.



Risks

- The company derive a significant portion of its revenue from the sale of products in certain therapeutic areas and any reduction in demand for these products could have an adverse effect on the business.
- The business is working capital intensive. If business experience insufficient cash flows from operations or are unable to borrow to meet the working capital requirements, it may materially and adversely affect the business and results of operations.

Promoters and Management Details

Nareshkumar Ramjibhai Patel - Executive Chairman and Managing Director Chetankumar Chhaganlal Vaghasia - Whole-time Director Virendra Nath Mishra - Whole-time Director